A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischaemic Stroke Patients

Trial Profile

A Phase IIb Prospective, Randomized, Double-blind, Placebo Controlled Study of NTx-265: Human Chorionic Gonadotropin (hCG) and Epoetin Alfa (EPO) in Acute Ischaemic Stroke Patients

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 18 Sep 2014

At a glance

  • Drugs NTx 265 (Primary) ; NTx 265 (Primary)
  • Indications Stroke
  • Focus Adverse reactions
  • Acronyms REGENESIS US
  • Sponsors Stem Cell Therapeutics Inc.
  • Most Recent Events

    • 18 Sep 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top